In the last trading session, 1.04 million Organogenesis Holdings Inc (NASDAQ:ORGO) shares changed hands as the company’s beta touched 1.71. With the company’s per share price at $5.01 changed hands at -$0.24 or -4.57% during last session, the market valuation stood at $635.41M. ORGO’s last price was a discount, traded about -33.93% off its 52-week high of $6.71. The share price had its 52-week low at $2.16, which suggests the last value was 56.89% up since then. When we look at Organogenesis Holdings Inc’s average trading volume, we note the 10-day average is 1.79 million shares, with the 3-month average coming to 1.71 million.
Analysts gave the Organogenesis Holdings Inc (ORGO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ORGO as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Organogenesis Holdings Inc’s EPS for the current quarter is expected to be -0.03.
Organogenesis Holdings Inc (NASDAQ:ORGO) trade information
Instantly ORGO was in red as seen at the end of in last trading. With action -2.81%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 56.56%, with the 5-day performance at -2.81% in the red. However, in the 30-day time frame, Organogenesis Holdings Inc (NASDAQ:ORGO) is 36.89% up. Looking at the short shares, we see there were 8.62 million shares sold at short interest cover period of 2.9 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 16.5% from its current market value. According to analyst projections, ORGO’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -19.76% plunge from its current level, while the stock would need to soar -19.76% for it to hit the projected low.
Organogenesis Holdings Inc (ORGO) estimates and forecasts
Year-over-year growth is forecast to reach 1.29% up from the last financial year.
Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of 90.77M. 3 analysts are of the opinion that Organogenesis Holdings Inc’s revenue for the current quarter will be 102.17M. The company’s revenue for the corresponding quarters a year ago was 109.98M and 130.23M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -17.47%. The estimates for the next quarter sales put growth at -21.55%.
The 2025 estimates are for Organogenesis Holdings Inc earnings to increase by 626.00%.
ORGO Dividends
Organogenesis Holdings Inc is expected to release its next quarterly earnings report on 2025-Feb-26.
Organogenesis Holdings Inc (NASDAQ:ORGO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 46.66% of Organogenesis Holdings Inc shares while 49.76% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 93.28%. There are 49.76% institutions holding the Organogenesis Holdings Inc stock share, with MORGAN STANLEY the top institutional holder. As of 2024-06-30, the company held 8.7789% of the shares, roughly 11.58 million ORGO shares worth $32.41 million.
SOLEUS CAPITAL MANAGEMENT, L.P. holds the second largest percentage of outstanding shares, with 8.6888% or 11.52 million shares worth $32.25 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund . With 1.95 shares estimated at $9.78 million under it, the former controlled 1.54% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 1.15% of the shares, roughly 1.46 shares worth around $7.32 million.
